香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Pharmaron Beijing Co., Ltd.* 康 龍 化 成（ 北 京 ）新 藥 技 術 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） 承董事會命 康龍化成（北京）新藥技術股份有限公司 主席 樓柏良博士 中華人民共和國，北京 2023年8月11日 於本公告日期，董事會包括執行董事樓柏良博士、樓小強先生及鄭北女士；非執 行董事胡柏風先生及李家慶先生；獨立非執行董事周其林先生、李麗華女士、曾 坤鴻先生及余堅先生。 * 僅供識別 （股份代號：3759） 董事會會議通告 康龍化成（北京）新藥技術股份有限公司（「本公司」）董事會（「董事會」）謹此宣 佈，董事會會議將於2023年8月25日（星期五）舉行，藉以（其中包括）審議及批准 本公司及其附屬公司截至2023年6月30日止六個月之中期業績。 ...

Incentive Plans - The company granted rewards under the 2022 A-share incentive plan on July 28, 2022, with the closing price prior to the grant being RMB 82.37[1] - The first phase of the H-share incentive trust plan granted rewards on April 1, 2022, and May 31, 2022, with closing prices of HKD 63.28 and HKD 59.38 respectively prior to the grants[1] Annual Report - The announcement does not affect other information disclosed in the 2022 annual report, which remains unchanged[2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Pharmaron Beijing Co., Ltd.* 康龍化成（北京）新藥技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3759） 補充公告 有關截至2022年12月31日止年度的年報 的進一步資料 茲提述康龍化成（北京）新藥技術股份有限公司（「本公司」）截至2022年12月31日 止年度的年報（「2022年年報」）。除非另有定義，本公告所用詞彙與2022年年報所 界定者具有相同涵義。 除於2022年年報所載董事會報告「股份激勵計劃」一段及綜合財務報表附註40所披 露的資料外，本公司謹此提供有關根據上市規則第17.07(1)(c)條於報告期內根據 2022年A股激勵計劃及首期H股獎勵信託計劃授予各獎勵的進一步詳情。 於報告期內，本公司股份於緊接根據2022年A股激勵計劃及首期H股獎勵信託計 劃授予獎勵日期前的收市價載列如下： 2022年A股激勵計劃 ...

证券代码：300759 证券简称：康龙化成 | --- | --- | --- | |----------------|----------------------------------------|--------------------------------| | | | 2023-05 | | | □特定对象调研 □ | | | | □媒体采访 □ | | | 投资者关系 | | | | | □新闻发布会 □ | | | 活动类别 | | | | | □现场参观 | | | | √其他 （股东大会） | | | | 叶*、赵**、安*、杨** | 、徐**、常**、陈**、徐**、陶** | | 参与单位名称及 | | | | | 李*、季** | AIHC、中信建投 | | 人员姓名 | | | | | 证券、民生证券、夏尔投资等 | 名个人及机构投资者参与 | | 间 | 2023 年 06 月 21 日 | | | | 北京市大兴区北京经济技术开发区荣华中路 | 19 号院朝林广场 A 座 5 层 | | 点 | | | | | 聚缘殿 | | | | 董事长、首席执行官 | 先生 | | | ...

Financial Performance - The company reported a revenue of CNY 2,723,970,949.97 for Q1 2023, representing a 29.53% increase compared to CNY 2,102,899,933.93 in the same period last year[4] - Net profit attributable to shareholders reached CNY 348,255,328.87, up 39.81% from CNY 249,086,573.60 year-on-year[4] - The adjusted net profit under non-IFRS was CNY 438,339,247.42, reflecting a 20.29% increase from CNY 364,396,375.05 in the previous year[4] - The company achieved a net cash flow from operating activities of CNY 530,139,954.34, which is a 26.89% increase from CNY 417,792,056.81 in the same quarter last year[4] - Total operating revenue for Q1 2023 reached CNY 2,723,970,949.97, a 29.5% increase from CNY 2,102,899,933.93 in Q1 2022[23] - Net profit for Q1 2023 was CNY 350,146,873.58, up 47.7% compared to CNY 236,952,176.60 in the same period last year[24] Earnings and Margins - The gross margin for the main business improved to 35.78%, up 2.61 percentage points from 33.17% in the previous year[8] - The basic earnings per share increased to CNY 0.2952, up 40.37% from CNY 0.2103 in the same period last year[4] - Basic earnings per share increased by 40.37% to 0.2952 compared to the same period last year, primarily due to an increase in net profit attributable to shareholders[12] - Diluted earnings per share rose by 40.59% to 0.2951, driven by the same factors as basic earnings[12] Cash Flow and Assets - Cash and cash equivalents increased by 372.6 million RMB, a growth of 37.26% from the beginning of the year[12] - The total current assets as of March 31, 2023, amounted to RMB 6,558,583,630.24, showing a slight increase from RMB 6,536,006,646.99 at the beginning of the year[20] - Cash and cash equivalents increased to RMB 2,055,504,003.16 from RMB 1,497,483,832.74, representing a growth of approximately 37%[20] - The company's long-term equity investments increased to RMB 638,223,819.28 from RMB 629,971,822.34, a rise of about 1.98%[20] - The total cash and cash equivalents at the end of Q1 2023 were CNY 1,990,475,525.11, a decrease from CNY 2,443,525,549.66 at the end of Q1 2022[27] Expenses and Investments - Research and development expenses surged by 93.81% to 76.84 million RMB, reflecting the company's commitment to enhancing R&D capabilities[12] - Management expenses rose by 42.63% to 414.38 million RMB, primarily due to an increase in personnel costs associated with business expansion[12] - Investment income increased significantly by 588.88% to 16.79 million RMB, attributed to higher investment returns from affiliated enterprises[12] - The company reported an investment income of CNY 16,791,039.74, a significant increase from CNY 2,437,442.71 in the previous year[23] Strategic Initiatives - The company continues to focus on a "full-process, integrated, and international" development strategy, with significant contributions from the top 20 global pharmaceutical companies[8] - The company announced a new equity incentive plan for 2023, aimed at aligning employee interests with company performance[18] - The company is actively participating in private equity investments, including a partnership with Wuxi AstraZeneca Zhongjin Venture Capital[17] - The company plans to expand its market presence through strategic investments and potential acquisitions in the biopharmaceutical sector[17] Liabilities and Equity - The total assets at the end of the reporting period were CNY 21,047,569,183.56, reflecting a 2.71% increase from CNY 20,492,557,228.07 at the end of the previous year[4] - Total liabilities rose to CNY 9,772,959,379.20, an increase from CNY 9,652,689,512.90, marking a 1.2% growth year-over-year[22] - The total equity attributable to shareholders of the parent company increased to CNY 10,979,426,501.16, up from CNY 10,548,615,357.20, reflecting a growth of 4.1%[22]

Financial Performance - The company reported a revenue of CNY 2,723,970,949.97 for Q1 2023, representing a 29.53% increase compared to CNY 2,102,899,933.93 in the same period last year[4] - Net profit attributable to shareholders reached CNY 348,255,328.87, up 39.81% from CNY 249,086,573.60 year-on-year[4] - The adjusted net profit attributable to shareholders under non-IFRS was CNY 438,339,247.42, reflecting a 20.29% increase from CNY 364,396,375.05 in the previous year[4] - Basic earnings per share increased by 40.37% to CNY 0.2952, driven by the overall positive development and expanding revenue scale[9] - The company reported a net profit of RMB 350,148,000 for the period, compared to RMB 236,953,000 in the previous year, marking an increase of about 47.7%[39] - For Q1 2023, the profit attributable to the parent company was RMB 348,255 thousand, an increase from RMB 249,087 thousand in Q1 2022[45] - The adjusted net profit attributable to the parent company under non-IFRS was RMB 438,339 thousand, reflecting a 20.3% increase compared to RMB 364,396 thousand in the same period last year[45] Revenue Breakdown - Revenue from laboratory services was CNY 1,652,771,147.35, with a year-on-year increase of 29.73%[5] - Revenue from North American clients accounted for 66.64% of total revenue, growing 34.74% year-on-year[6] - Revenue from European clients (including the UK) represented 14.81% of total revenue, increasing by 38.12% compared to the previous year[6] Cost and Expenses - Total operating costs amounted to ¥2,352,273,096.85, up 28% from ¥1,838,358,908.07 in the prior period[21] - Research and development expenses surged by 93.81% to CNY 76,838,901.31, reflecting the company's commitment to enhancing R&D capabilities[10] - Research and development expenses increased to ¥76,838,901.31, up 93.9% from ¥39,647,299.50 in the prior period, highlighting a focus on innovation[23] Cash Flow and Liquidity - Cash flow from operating activities for the period was CNY 530,139,954.34, a 26.89% increase from CNY 417,792,056.81 in the previous year[4] - Cash and cash equivalents rose by 37.26% to CNY 2,055,504,003.16, an increase of CNY 558,020,200[9] - Cash and cash equivalents at the end of the period amounted to RMB 1,990,475,525.11, compared to RMB 2,443,525,549.66 at the end of the previous period[35] Assets and Liabilities - The total current assets as of March 31, 2023, amounted to CNY 6,558,583,630.24, showing a slight increase from CNY 6,536,006,646.99 at the beginning of the year[16] - The total non-current assets reached CNY 14,488,985,553.32, compared to CNY 13,956,550,581.08 at the beginning of the year, reflecting a growth of approximately 3.8%[17] - Total liabilities increased to ¥9,772,959,379.20 from ¥9,652,689,512.90 at the beginning of the year, marking a rise of 1.2%[19] - Non-current liabilities totaled RMB 5,838,198 thousand as of March 31, 2023, compared to RMB 5,740,256 thousand at the end of 2022[42] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 63,326[11] - The largest shareholder, HKSCC NOMINEES LIMITED, held 16.87% of the shares, totaling 201,001,393 shares[12] - The company's major shareholders include HKSCC NOMINEES LIMITED with 201,001,393 shares and Shenzhen Xinchongkangcheng Investment Partnership with 178,735,472 shares[13] Strategic Focus - The company continues to focus on a "full-process, integrated, and international" development strategy, with significant business presence in both China and overseas markets[6] - The company has completed the integration of its capabilities in large molecule and cell and gene therapy services, enhancing its service offerings[5] Other Financial Metrics - The company received government subsidies related to daily activities amounting to CNY 18,969,599.72, which contributed to other income growth of 108.49%[10] - The company reported a total comprehensive income of ¥349,276,609.52 for the current period, significantly higher than ¥181,924,551.84 in the previous period[28] - The total liabilities to equity ratio stands at approximately 86.7%, indicating a stable leverage position for the company[19]

证券代码：300759 证券简称：康龙化成 康龙化成（北京）新药技术股份有限公司投资者关系活动记录表 编号：2023-02 | □特定对象调研 | □分析师会议 | | --- | --- | | | □媒体采访 □业绩说明会 | | 活动类别 | | | | □现场参观 | | | √其他 （电话会议） | | 参与单位名称及 | International, Inc.中国人保、华夏基金、银华基金、嘉实资产、广发基金、 | | | 华夏基金、建信养老、国寿养老、太平养老、平安养老、新华养老、中 | | | 国人寿、阳光资产、平安资产、富国基金、博时基金、鹏华基金、汇添 | | | 富基金、泰达宏利基金、天弘基金、海富通基金、中银基金、太平基金、 | | | 上投摩根基金、英大国际信托等 余家机构 余名参与人员 400 410 | | | 日 31 09:00-11:30 | | 地 点 | 公司会议室 | | 上市公司接待人 | | | 员姓名 | | | | 首席财务官、董事会秘书：李承宗先生 | | 投资者关系活动 | 年度报告 2022 进行分析解读。 2022 年度，公司实现营业收入超过 100 亿 ...

Financial Performance - The company reported a total revenue of RMB 1.5 billion for the year 2022, representing a year-over-year increase of 25%[142]. - The company achieved a revenue of 1,026,628.82 million yuan in 2022, representing a year-on-year growth of 37.92%[30]. - The company reported a significant increase in revenue, reaching approximately 1.5 billion RMB, representing a year-over-year growth of 25%[10]. - The company provided a revenue guidance for 2023, expecting a growth rate of 20% to 25%[143]. - The company provided a positive outlook for 2023, projecting a revenue growth of 20% to 25% based on new product launches and market expansion strategies[10]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the year, representing a growth of 25% year-over-year[132]. - The company reported a revenue increase of 25% year-over-year, reaching CNY 1.5 billion in 2022[135]. - The company achieved a total operating revenue for 2022 of ¥10,266,288,179.53, representing a 37.92% increase from ¥7,443,769,724.38 in 2021[58]. Profitability - The net profit attributable to shareholders for 2022 was ¥1,374,604,224.18, a decrease of 17.24% from ¥1,661,028,567.53 in 2021[14]. - The adjusted net profit attributable to shareholders was 183,427.10 million yuan, an increase of 25.46% compared to the previous year[30]. - The overall gross margin improved to 45%, up from 40% in the previous year, reflecting better operational efficiency and cost management[10]. - The gross margin for the main business reached 36.73%, up by 0.71 percentage points from the previous year[30]. - The gross profit margin for the scientific research and technology services sector improved slightly to 36.73%, up from 36.48% in the previous year[60]. Investment and R&D - Investment in R&D increased by 15%, totaling 300 million RMB, focusing on innovative drug development and advanced technologies[10]. - The R&D budget for 2023 is set at RMB 300 million, a 20% increase from the previous year[143]. - The company invested CNY 200 million in R&D for new technologies, focusing on advanced drug delivery systems[135]. - The company has established a comprehensive drug development service platform, focusing on small molecule research and development, and is expanding capabilities in large molecule and gene therapy services[91]. - The company is investing 150 million RMB in new technology for drug discovery to improve efficiency[132]. Market Expansion - The company plans to expand its market presence in Europe and North America, targeting a 10% market share in these regions by 2025[10]. - The company aims to strengthen its international service platform to provide cross-disciplinary and cross-regional solutions for clients[23]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2025[143]. - The company is actively pursuing mergers and acquisitions to strengthen its portfolio, with a budget of 500 million RMB allocated for potential acquisitions in 2023[10]. - The company is planning to expand its market presence in Asia, targeting a 20% increase in market share by 2025[122]. Client and Customer Engagement - User data showed that the number of active clients increased by 30%, reaching a total of 1,200 clients in 2022[10]. - User data showed an increase in active users by 30% year-over-year, reaching 2 million active users by the end of 2022[143]. - The company introduced approximately 800 new clients in 2022, diversifying its customer base[30]. - Customer satisfaction ratings improved to 85%, reflecting a 5% increase from the previous year[143]. Strategic Partnerships and Acquisitions - A new strategic partnership was announced with a leading pharmaceutical company to enhance drug development capabilities and accelerate commercialization efforts[10]. - The company completed a strategic acquisition to enhance its research capabilities, which is expected to contribute an additional 4,920,000 in revenue[119]. - The company completed an acquisition of a biotech firm for CNY 500 million, enhancing its product pipeline[135]. - The company is exploring partnerships with international firms to enhance its global reach and innovation[142]. Risk Management - The company emphasizes the importance of risk management and outlines potential risks and countermeasures in its future development outlook[3]. - The company has implemented measures to control market, liquidity, credit, operational, and legal risks associated with its hedging activities[83]. - The company has established a management system for futures and derivatives trading, ensuring compliance with operational norms and risk control measures[83]. Governance and Compliance - The company emphasizes innovation and technology development, focusing on chemical and biological technology platforms to meet evolving R&D demands[54]. - The company has established a sound governance structure, with independent committees providing professional decision-making support to the board[108]. - The company has implemented a financial decision-making process in accordance with its articles of association, allowing for independent financial management[112]. - The company has not reported any significant changes in accounting policies or principles related to hedging activities compared to the previous reporting period[82]. Environmental Responsibility - The company has complied with various environmental protection laws and standards applicable to its operations[192]. - The company has received multiple environmental impact assessment approvals for its new drug research and development projects from 2010 to 2021[192]. - The company has a wastewater treatment project in Xi'an with a capacity of 120 tons/day, which received environmental impact report approval in August 2020[195]. - The company reported a total wastewater discharge of 10.088 tons for CODcr, with no exceedance of discharge standards[199]. Workforce and Talent Management - The company expanded its workforce to 19,481 employees by the end of 2022, with 89.35% in R&D, production technology, and clinical services[30]. - The number of R&D personnel grew by 29.36% to 17,406, with a slight decrease in the proportion of R&D personnel to total staff[66]. - The company has implemented a talent development platform, including internal training and partnerships with renowned institutions, to attract and cultivate top global talent[55]. - The company has established a comprehensive training program to enhance employee skills and align personal development with corporate strategy[160]. Financial Management - The company has established a robust internal control and audit system to monitor financial activities and identify risks[185]. - The company has enhanced its financial reporting and tax management systems, improving efficiency and accuracy in financial forecasting and tax risk assessment[181]. - The company has integrated its subsidiaries into a unified management system, ensuring accurate consolidated financial reporting and operational efficiency[184]. - The total pre-tax remuneration for the company's directors, supervisors, and senior management in 2022 amounted to CNY 1,339.22 million[148].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Pharmaron Beijing Co., Ltd.* 康龍化成（北京）新藥技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3759） 截至2022年12月31日止年度全年業績公告 財務摘要及要點 截至12月31日止年度 2022年 2021年 變動 人民幣千元 人民幣千元 % 收益 10,266,288 7,443,770 37.9 毛利 3,749,276 2,672,044 40.3 母公司擁有人應佔利潤 1,374,604 1,661,029 (17.2) 母公司擁有人應佔非國際財務報告 準則經調整淨利潤 1,834,271 1,461,985 25.5 經營活動所得現金流量淨額 2,142,816 2,058,044 4.1 － 於報告期間，本集團錄得總收益約人民幣10,266.3百萬元，較截至2021年 12月31日止年度增加約人民幣2,822.5百萬元或37.9% ...